<DOC>
	<DOCNO>NCT00003725</DOCNO>
	<brief_summary>RATIONALE : Transurethral resection less invasive type surgery bladder cancer may fewer side effect improve recovery . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether transurethral resection plus AD 32 effective transurethral resection alone bladder cancer . PURPOSE : Randomized phase III trial compare effectiveness transurethral resection surgery follow AD 32 transurethral resection alone treat patient newly diagnose recurrent bladder cancer .</brief_summary>
	<brief_title>Surgery With Without Chemotherapy Treating Patients With Newly Diagnosed Recurrent Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess efficacy adjuvant AD 32 follow complete transurethral resection versus transurethral resection alone patient newly diagnose recurrent superficial transitional cell carcinoma bladder . II . Assess toxicity AD 32 patient . OUTLINE : This open label , randomize , multicenter study . Patients randomize receive surgery AD 32 surgery alone . Arm I : Patients undergo surgery remove bladder tumor . AD 32 administer catheter bladder within 2-24 hour surgery . Patients must hold AD 32 liquid bladder 90 minute . Arm II : Patients undergo surgery remove bladder tumor . Patients T1 Tis disease may receive BCG therapy weekly 6 week , follow 6 week rest . Patients follow every 3 month 2 year . PROJECTED ACCRUAL : This study accrue approximately 300 patient .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Valrubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose stage 0 ( Ta ) , stage I , recurrent superficial transitional cell carcinoma bladder Must least 2 papillary appear bladder tumor cystoscopic examination Patients recurrent disease must history Tis tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : WBC great 4000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT great 2 time ULN Renal : Creatinine great 2 time ULN Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biological response modifier bladder cancer Chemotherapy : No prior concurrent chemotherapy bladder cancer No prior AD 32 therapy bladder cancer Endocrine therapy : Not specify Radiotherapy : No prior concurrent radiotherapy Surgery : At least 9 month since complete transurethral resection bladder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>